Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1) (NCT07288723) | Clinical Trial Compass
CompletedNot Applicable
Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1)
Guadeloupe88 participantsStarted 2023-04-06
Plain-language summary
Chronic kidney disease (CKD) is a major global public health issue. The present project focuses on the role of apolipoprotein L1 (APOL1) in patients with stage 4 CKD (glomerular filtration rate between 15 and 29 mL/min/1.73 m²).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients 18 y and older, of both sexes, Afro Caribbeans
* Living in Guadeloupe
* Having been informed of objectives and constraints of the study and who have given their written consent.
* For patients with CKD : at stage 4 (GFR \< than 30 ml / min / 1.73m2.), whatever the etiology of CKD, associated pathologies and treatments,
* For patients with normal renal function : serum creatinine \< 10 mg/l.
Exclusion Criteria:
* Patients 18 y and older, of both sexes, Afro Caribbeans
* Living in Guadeloupe
* Having been informed of objectives and constraints of the study and who have given their written consent.
* For patients with CKD : at stage 4 (GFR \< than 30 ml / min / 1.73m2.), whatever the etiology of CKD, associated pathologies and treatments,
* For patients with normal renal function : serum creatinine \< 10 mg/l.
What they're measuring
1
Frequency of alleles (G1 and G2) of APOL1
Timeframe: At baseline (study inclusion).
Trial details
NCT IDNCT07288723
SponsorCentre Hospitalier Universitaire de la Guadeloupe